Waters Launches Industry-First Bioseparation Columns, Delivering Up to 3x Faster GLP-1 Characterization
WAT sits 37% above its 52-week low of $275.05.
Summary
Waters Corporation launched new BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns, which are described as industry-first reversed-phase bioseparation columns. These new products are designed to deliver up to 3x faster GLP-1 characterization and 2x faster LNP component analysis, along with a 2x increase in resolving power and sensitivity. This innovation aims to accelerate biopharmaceutical development timelines and reduce production bottlenecks by improving the separation of impurities in critical drug substances like GLP-1 peptides and lipid nanoparticles. This launch continues a pattern of recent product introductions and regulatory clearances for Waters, highlighting ongoing innovation in its analytical sciences portfolio.
At the time of this announcement, WAT was trading at $377.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $35.9B. The 52-week trading range was $275.05 to $414.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.